

## S 2327

### Seniors Prescription Drug Relief Act

**Congress:** 117 (2021–2023, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Jul 13, 2021

**Current Status:** Read twice and referred to the Committee on Finance.

**Latest Action:** Read twice and referred to the Committee on Finance. (Jul 13, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/senate-bill/2327>

### Sponsor

**Name:** Sen. Cassidy, Bill [R-LA]

**Party:** Republican • **State:** LA • **Chamber:** Senate

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Menendez, Robert [D-NJ]	D · NJ		Jul 13, 2021

### Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Jul 13, 2021

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
117 HR 5237	Related bill	<b>Nov 1, 2022:</b> Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
117 HR 5260	Related bill	<b>Nov 1, 2022:</b> Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
117 HR 8588	Related bill	<b>Nov 1, 2022:</b> Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
117 HR 5376	Related bill	<b>Aug 16, 2022:</b> Became Public Law No: 117-169.

## **Seniors Prescription Drug Relief Act**

This bill establishes and alters several programs and requirements relating to the prices of prescription drugs under Medicare.

For example, the bill caps annual out-of-pocket spending under the Medicare prescription drug benefit. It also establishes (1) a program under which drug manufacturers must, subject to civil penalties, provide discounts for covered drugs for beneficiaries who have incurred costs above the annual deductible; and (2) a process through which certain beneficiaries may have their monthly out-of-pocket costs capped and paid in monthly installments.

## **Actions Timeline**

---

- **Jul 13, 2021:** Introduced in Senate
- **Jul 13, 2021:** Read twice and referred to the Committee on Finance.